2006
DOI: 10.1016/j.nbd.2005.12.006
|View full text |Cite
|
Sign up to set email alerts
|

DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

7
198
0
3

Year Published

2007
2007
2017
2017

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 205 publications
(208 citation statements)
references
References 49 publications
7
198
0
3
Order By: Relevance
“…DYRK1A transgenic (Tg) mouse models were also made in an effort to reveal its role in DS. Cognitive deficits were noted in two models overexpressing DYRK1A, one under the sheep metallothionein 1a (sMT-1a) promoter (24) and the other in a BAC under the human DYRK1A promoter (23). Although original reports of these two models did not mention changes in body weight, a recent study showed that DYRK1A BAC Tg mice are lean and resistant to diet-induced obesity (62).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…DYRK1A transgenic (Tg) mouse models were also made in an effort to reveal its role in DS. Cognitive deficits were noted in two models overexpressing DYRK1A, one under the sheep metallothionein 1a (sMT-1a) promoter (24) and the other in a BAC under the human DYRK1A promoter (23). Although original reports of these two models did not mention changes in body weight, a recent study showed that DYRK1A BAC Tg mice are lean and resistant to diet-induced obesity (62).…”
Section: Discussionmentioning
confidence: 99%
“…It binds DYRK1A, a dual-specificity tyrosine phosphorylationregulated kinase that is encoded by a gene located on chromosome 21 and is overexpressed in Down syndrome (DS) (22). DYRK1A is a major candidate gene in producing features of DS, and transgenic mice overexpressing DYRK1A show cognitive and behavioral alterations similar to those in persons with DS (23,24). Also, recent studies show that administration of epigallocatechin-3-gallate (EGCG), which antagonizes DYRK1A, can improve the cognitive function of individuals with DS (25,26).…”
mentioning
confidence: 99%
“…Stereological studies on heterozygous mice with one copy of DYRK1A have shown that changes in the dosage of this gene induce an increase in pyramidal cell density, together with lower levels of dendritic arborization (Benavides-Piccione et al, 2005). A recent study (Ahn et al, 2006) with BAC transgenic mice carrying one extra copy of the human DYRK1A gene also reported phenotypic alterations, including an increase in brain weight and cognitive impairment: these results confirm that the modifications seen in YAC152F7 transgenic mice are due to DYRK1A overexpression and that a change in DYRK1A gene dosage may have both morphological and behavioral consequences.…”
Section: Discussionmentioning
confidence: 99%
“…For Down syndromerelated studies, it has the added attraction of being the most commonly used test, providing a robust phenotype in many mouse models (Escorihuela et al 1998;Sago et al 1998;Chabert et al 2004;Martinez-Cue et al 2005;Ahn et al 2006). There are, however, significant drawbacks to using the MWM when assaying a molecular phenotype.…”
Section: Discussionmentioning
confidence: 99%